Inhibikase Therapeutics Inc./$IKT
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases, namely, Pulmonary Arterial Hypertension (PAH), in which aberrant signaling through type III receptor tyrosine kinases, including platelet derived growth factor receptors and a stem cell factor receptor, known as c-Kit, has been implicated. Its product candidate is IKT-001, a prodrug of imatinib mesylate (imatinib), for PAH which is an orphan indication. The company has developed its own portfolio of protein kinase inhibitors to treat bacterial and viral infections, including viral infections in the brain. It has one reporting segment, which is the business of developing protein kinase inhibitor therapeutics.
Ticker
$IKT
Sector
Primary listing
Employees
35
Headquarters
Website
IKT Metrics
BasicAdvanced
$331m
-
-$0.49
0.86
-
Price and volume
Market cap
$331m
Beta
0.86
52-week high
$2.30
52-week low
$1.33
Average daily volume
1.1m
Financial strength
Current ratio
21.698
Quick ratio
21.536
Profitability
EBITDA (TTM)
-53.288
Management effectiveness
Return on assets (TTM)
-20.53%
Return on equity (TTM)
-36.05%
Valuation
Price to book
1.91
Price to tangible book (TTM)
1.91
Price to free cash flow (TTM)
-6.754
Free cash flow yield (TTM)
-14.81%
Free cash flow per share (TTM)
-0.287
Growth
Earnings per share change (TTM)
-57.70%
3-year earnings per share growth (CAGR)
-51.40%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Inhibikase Therapeutics Inc. stock?
Inhibikase Therapeutics Inc. (IKT) has a market cap of $331M as of May 05, 2026.
What is the P/E ratio for Inhibikase Therapeutics Inc. stock?
The price to earnings (P/E) ratio for Inhibikase Therapeutics Inc. (IKT) stock is 0 as of May 05, 2026.
Does Inhibikase Therapeutics Inc. stock pay dividends?
No, Inhibikase Therapeutics Inc. (IKT) stock does not pay dividends to its shareholders as of May 05, 2026.
When is the next Inhibikase Therapeutics Inc. dividend payment date?
Inhibikase Therapeutics Inc. (IKT) stock does not pay dividends to its shareholders.
What is the beta indicator for Inhibikase Therapeutics Inc.?
Inhibikase Therapeutics Inc. (IKT) has a beta rating of 0.86. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.